Generation Biotech

Karl P Dresdner, Jr

Johannes Dapprich

Richard R McKay

Nathan A Beckham

Michael Raymond Cary

Chase Hudson

The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness less than 300 nanometers, wherein the AQTP has an improved bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors. The invention provides compositions comprising of AQTP which comprise a substance selected from the group consisting of a cannabinoid such as CBD, a cell membrane pore-forming peptide such as PNC-27, a psychoactive drug, a pharmaceutical, a nutraceuticals, a mineral, an anion, a cation, a protein, a peptide, an amino acid, a polymer, a vitamins, an antioxidants, a fertilizer, a chemical, a medical use product, a medical kit use product, a personal consumer use product, a manufacturing use product, a energy use product such as a battery, and any combination thereof.

Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness

The invention relates to methods for capturing a polynucleotide comprising a DNA target segment from a population of polynucleotide molecules using a rotation of a magnetic field to move streptavidin-labeled magnetic beads relative to a buffered liquid medium to increase the probability of capturing and preventing damage to a long polynucleotide comprising a DNA target segment. The methods may use a rotation of the magnetic field relative to the mixture or a rotation of the mixture relative to the magnetic field for causing magnetic bead rotation in the buffered liquid medium and increasing the binding of biotinylated nucleotides of an extended polynucleotide primer to streptavidin-labeled magnetic beads, and winding or condensation of a polynucleotide onto the streptavidin-labeled magnetic beads to prevent damage to the long polynucleotide comprising a DNA target segment.

Growing community of inventors

Haddonfield, NJ, United States of America

Karl P Dresdner, Jr